☆ 4.6 Article

Abstract C197: A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors

MOLECULAR CANCER THERAPEUTICS (2012)

Get Full Text
Add to Collection

Journal

MOLECULAR CANCER THERAPEUTICS
Volume 8, Issue Supplement 1, Pages C197-C197

Publisher

American Association for Cancer Research (AACR)
DOI: 10.1158/1535-7163.targ-09-c197

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.